TABLE 9.
In vitro activities of NS5A inhibitors against NS5A P32deletion with or without additional NS5A substitutions in the HCV GT1b-Con1 replicon
| NS5A inhibitor | Mean EC50 ± SD (pM) for wild-type GT1b | P32deletion |
L31F + P32deletion |
||
|---|---|---|---|---|---|
| Mean EC50 ± SD (pM) | Fold change in EC50 | Mean EC50 ± SD (pM) | Fold change in EC50 | ||
| Pibrentasvir | 1.9 ± 0.8 | 1,968 ± 203 | 1,036 | 38,877 ± 1,227 | 20,461 |
| Ombitasvir | 0.79 ± 0.25 | 1,363,857 ± 347,809 | 1,726,401 | 1,076,900 ± 214,654 | 1,363,165 |
| Daclatasvir | 10.6 ± 2.0 | 3,497,200 ± 1,004,375 | 329,925 | 4,127,000 ± 224,301 | 389,340 |
| Elbasvir | 3.2 ± 1.4 | 368,900 ± 176,726 | 115,281 | 321,900 ± 61,946 | 100,594 |
| Ledipasvir | 1.6 ± 0.62 | 845,233 ± 104,697 | 528,271 | 723,967 ± 54,768 | 452,479 |
| Velpatasvir | 4.8 ± 0.77 | 196,200 ± 30,448 | 40,875 | 302,133 ± 20,880 | 62,944 |